Compare NetFlix Inc (NFLX) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetFlix Inc vs Recursion Pharmaceuticals Inc — how do they compare? NetFlix Inc trades at $76.53 (market cap $319.67B), while Recursion Pharmaceuticals Inc trades at $3.24 (market cap $1.86B). The key difference: NetFlix Inc is far larger — about 171.9× Recursion Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| NFLX | RXRX | |
|---|---|---|
Market Cap | $319.67B | $1.86B |
Sector | Consumer Cyclical | Health |
52-Week High | $124.77 | $6.79 |
52-Week Low | $67.60 | $2.84 |
Enterprise Value | $324.85B | $1.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Netflix (NFLX) is trading at $76.03, down 2.84% on the day, amid a bearish technical signal and recent price weakness. The stock is near its 52-week low, with support at $76 and resistance at $78. Fundamentally, the company shows strong revenue growth, with 2025 revenue at $45.18 billion and net income of $10.98 billion, and has beaten EPS estimates for the last three quarters. Analyst sentiment remains largely positive with a consensus buy rating and price target of $88.95, though recent news highlights concerns over the stock's performance streak.
The outlook for NFLX is mixed; strong fundamentals and analyst optimism suggest potential upside, but technical bearishness and competitive pressures pose risks. Investors should weigh robust profitability and ad-tier expansion against market volatility and execution challenges in the streaming sector.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NetFlix Inc
Netflix Inc. is an Internet subscription service for watching television shows and movies. Subscribers can instantly watch unlimited television shows and movies streamed over the Internet to their televisions, computers, and mobile devices and in the United States, subscribers can receive standard definition DVDs and Blu-ray Discs delivered to their homes.
Read more on NFLX →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
